1246820-85-8

Sotalol-d₆ is intended for use as an internal standard for the quantification of sotalol by GC- or LC-MS. Sotalol is a non-selective antagonist of β-adrenergic receptors (β-ARs; IC₅₀s = 8.9 and 5.2 μM for β1- and β2-ARs, respectively) and a class III antiarrhythmic agent. It decreases delayed outward potassium currents (IK) in guinea pig ventricular cells and prolongs action potential duration in electrically stimulated isolated guinea pig papillary muscles when used at a concentration of 100 μM. Sotalol decreases heart rate and increases blood pressure and the cardiac functional refractory period (FRP) in a canine model of ventricular tachycardia induced by programmed electrical stimulation (PES). Formulations containing sotalol have been used in the treatment of ventricular arrhythmias and maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL).

A labelled potent α-adrenergic receptor antagonist. A class III antiarrythmic. It has been shown to prolong action potential and increases the refractory period.

[1] RANDALL LIS. Synthesis of novel (aryloxy)propanolamines and related compounds possessing both class II and class III antiarrhythmic activity[J]. Journal of Medicinal Chemistry, 1990, 33 10: 2883-2891. DOI: 10.1021/jm00172a033
[2] BS M J A, PHD  Allen G B, PHD. Pharmacology, pharmacodynamics and pharmacokinetics of sotalol[J]. American Journal of Cardiology, 1990, 65 2: Pages 12-21. DOI: 10.1016/0002-9149(90)90196-8
[3] KATSUHIDE KOMEICHI. Effects of N-acetylprocainamide and sotalol on ion currents in isolated guinea-pig ventricular myocytes[J]. European journal of pharmacology, 1990, 187 3: Pages 313-322. DOI: 10.1016/0014-2999(90)90358-d